Acute Coronary Syndrome: Getting to the Heart of the Matter for Pharmacists

Estimated time to complete activity: 1 hour
Date of initial release: June 18, 2018
Valid for CPE credit through: June 18, 2019

Instructions for Credit

There is no fee for this activity.  To receive credit after reading this CPE activity in its entirety, participants must review the accreditation and disclosure information, complete the pre-activity assessment, view the presentation in its entirety, and complete the posttest and evaluation.  For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or  MLI will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth.  Within 6 weeks, view your participation record at the NABP website: 

Please note that your participation will not show as ‘Completed’ on ASHP’s website as MLI is the accreditor for this activity and will be handling the credit fulfillment.


Use the button above (or click here) to enroll.  Activity is offered on another CE provider’s site.

Program Description

Acute coronary syndrome (ACS) is not just one disease but a group of disorders that can be thought of as a continuum of injury with the least severe being angina (UA), followed by non-ST elevation myocardial infarction (NSTEMI), and then the most severe, ST elevation myocardial infarction (STEMI). ACS is defined by the symptoms that result from acute myocardial ischemia caused by insufficient blood flow to the heart muscle. 

Pharmacists can assist patients across the continuum of care. However, studies have shown that many pharmacists are unprepared to manage their patients with ACS. In order for pharmacists to provide the best possible care and education for patients, they must be equipped with the most recent clinical data and resources. 

Pharmacists working in integrated healthcare delivery systems play a key role in affecting best practices and also help to evaluate the evidence supporting novel therapies and monitoring systems, so they can directly influence the uptake of innovations in the health system.

This program will educate and empower pharmacists to actively manage their patients with ACS or who may be at risk of ACS, so that they can maintain long-term optimal health.

Target Audience

This activity was developed for health-system pharmacists and pharmacy technicians that manage patients with Acute Coronary Syndrome (ACS).

Registered Pharmacy Designation

The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Completion of this application-based activity provides for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. 

Universal Activity Number: 0468-0000-18-010-H01-P
Universal Activity Number: 0468-0000-18-010-H01-T 

Learning Objectives

Upon completion of this activity, the participant will be able to:


  • Identify patients at risk for ACS
  • Explain the distinct phases of the continuum of IHD and ACS: UA, NSTEMI, and STEMI in order to assist the care team in managing patients as they progress through treatment
  • Review recent advances in treatment for the ACS/CAD patient to optimize outcomes
  • Summarize best practices to counsel patients on the importance of adherence and follow-up care while monitoring their ongoing health including coordinating all their prescriptions

Pharmacy Technicians

  • Explain the risk factors of ACS
  • Describe the differences between UA, NSTEMI and STEMI
  • Identify recent developments in the management of ACS
  • Recognize the importance of supporting patient information, adherence and outcomes

Course Faculty:

Toby C. Trujillo, PharmD, FCCP, FAHA, BCPS-AQ Cardiology
Associate Professor
University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Clinical Specialist - Anticoagulation/Cardiology
University of Colorado Hospital
Aurora, CO


           This activity is provided by Medical Learning Institute, Inc.


Commercial Support Acknowledgment

This activity is supported by an educational grant from AstraZeneca.